Fig. 2

Percentages of subjects with ≥ 50%, ≥ 70%, and ≥ 90% reductions in the number of monthly HAE attacks on active treatment relative to placebo and adjusted odds ratios. Adjusted data for the crossover study design variables sequence within treatment (period not included for convergence reasons); may vary slightly from previously reported unadjusted data. Five of the 45 patients in COMPACT had missing attack values (3 during the placebo period and 2 during the C1-INH[SC] 60 IU/kg period) and were excluded from analyses. Bars represent 95% CIs. Products were administered twice weekly. The observation period was 14 weeks for the COMPACT study (C1-INH[SC] data) and 12 weeks for the CHANGE study (C1-INH[IV] data). CI confidence interval, HAE hereditary angioedema, IU international units, IV intravenous, SC subcutaneous, U units